Targets › MBL
1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Oct 2027.
Calcium-dependent lectin, which acts as a pattern recognition receptor that initiates the lectin pathway of the complement system, a cascade of proteins that leads to phagocytosis and breakdown of pathogens and signaling that strengthens the adaptive immune system. Specifically recognizes and binds the mannose moiety of carbohydrates on the pathogen surface, activating the MASP1 serine protease and initiating the…. (UniProt, P11226)
Open in Phaseline: the race on MBL, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Menarini Group | Meropenem Bacterial penicillin-binding protein inhibitor | MBL | Phase 2 | Gram Negative Infections | Oct 2027 |
Gram Negative Infections (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.